3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Colorectal Neoplasms
3
Pancreatic Neoplasms
2
Triple Negative Breast Neoplasms
1
Ras-wildtype Colorectal Cancer
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
7
Radiotherapy
6
Radiosurgery
4
pembrolizumab
3
Specimen Handling
3
Paclitaxel
3
Fluorodeoxyglucose F18
3
Carboplatin
3
sargramostim
2
cediranib
2
Thiotepa
2
Radiation
2
Nivolumab
2
Melphalan
2
IFL protocol
2
Granulocyte Colony-Stimulating Factor
2
Genetic Testing
2
Gemcitabine
2
FAPI-46
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
tipifarnib
1
sodium thiosulfate
1
regorafenib
1
paclitaxel-Angiopep-2 conjugate
1
montelukast
1
etoposide phosphate
1
entrectinib
1
entinostat
1
clevudine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
Doxycycline
×
Gastrointestinal
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn